AGI-134

AGI-134 · Agalimmune Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AGI-134, covering 2025-02-14 to 2025-02-14. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour [Phase 1, Phase 2]